ALLMedicine™ Acneiform Eruptions Center
Research & Reviews 54 results
JAMA Dermatology; Okroglic L, Sohier P et. al.
Dec 1st, 2022 - A new treatment for cystic fibrosis combining 3 CFTR modulators-elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA)-has recently been approved for cystic fibrosis treatment. The cutaneous adverse effects following treatment with this combinat...
Journal of the American Academy of Dermatology; Bierbrier R, D'Aguanno K et. al.
Oct 14th, 2022 - Prognostic factors for the development of acneiform eruptions in patients on epidermal growth factor receptor inhibitors.|2022|Bierbrier R,D'Aguanno K,Kasymjanova G,Dell'Aniello S,Agulnik J,|
International Journal of Dermatology; Bathula S, Sardana K et. al.
Aug 5th, 2022 - Corticosteroids remain the main therapy in erythema nodosum leprosum (ENL), and long-term usage in chronic or recurrent ENL is a cause of significant morbidity and mortality. Thalidomide exerts dramatic effect in controlling ENL and helps reduce t...
Pediatric Dermatology; Gupta R, Craddock MF
Jul 28th, 2022 - Selumetinib is a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor (MEKi) approved to treat inoperable plexiform neurofibromas and used off-label for low-grade gliomas. Acneiform eruptions are a known complication of...
Supportive Care in Cancer : Official Journal of the Multi... Ibraheim MK, Lo J et. al.
Jul 1st, 2022 - Epidermal growth factor receptor inhibitors (EGFRI) can be used with pathway inhibitors, including mitogen-activated protein kinase kinase inhibitors (MEKIs), BRAF inhibitors (BRAFIs), and checkpoint inhibitors such as programmed death-ligand 1 (P...
Drugs 4 results see all →
Clinicaltrials.gov 2 results
Nov 11th, 2021 - Rosacea affects roughly 16 million Americans who desire better treatments than those currently available. Acne vulgaris, another chronic inflammatory skin disorder, mainly affects teenagers but also affects 20-40% of adults. Investigating potentia...
Sep 8th, 2021 - Background and Study Aims: Tyrosine Kinase inhibitors (TKIs) have become standard of care in patients with EGFR mutations in non-small cell lung cancer and other EGFR-mutated cancers. However, TKIs are well-known to cause cutaneous adverse events,...
News 16 results
Jun 3rd, 2022 - The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Acneiform eruptions in patients with colorectal cancer are more extensive and severe when targeted cancer therapie...
Oct 6th, 2021 - Tracey Liebman, MD Optimal management of treatment-related dermatologic adverse events (AEs) in patients with melanoma is essential for proper care, according to Tracey Liebman, MD. For the patients who develop nonspecific rash, pruritus or itch...
Dec 5th, 2020 - Mario E. Lacouture, MD Many patients being treated with mTOR inhibitors experience dermatologic-related adverse events. Dermatologic side effects can have a psychosocial effect on patients, by affecting areas of the body exposed to other peop...
Jul 30th, 2020 - NEW YORK (Reuters Health) - Skin reactions are common in youngsters on MEKI/BRAFI therapy, often resulting in alterations or interruptions in cancer therapy, according to a multicenter retrospective study. "Every child in our study developed at le...
Josh A. Hammel, MD, Dean Elhag, MD et. al.
Jan 27th, 2020 - To the Editor: The epidermal growth factor receptor (EGFR) signaling pathway plays a role in the differentiation, proliferation, and survival of several cell types. 1 Erlotinib is an EGFR inhibitor that targets aberrant cells that overexpress this.